Parkinson's
Case Western researchers identify alpha-synuclein–ClpP interaction that may drive Parkinson’s-related mitochondrial damage
Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo
Researchers at Case Western Reserve University report they have identified an abnormal interaction between the Parkinson’s-linked protein alpha-synuclein and the enzyme ClpP that disrupts mitochondrial function in experimental models. They also describe an experimental compound, CS2, designed to block that interaction, which they say improved movement and cognitive performance and reduced brain inflammation in lab and mouse studies.
Researchers in Sweden and Norway have identified biological markers in the blood that signal the earliest stages of Parkinson's disease, potentially allowing detection up to 20 years before motor symptoms appear. The study, published in npj Parkinson's Disease, highlights a brief window where these markers are detectable, offering hope for earlier diagnosis and treatment. Blood tests based on this discovery could enter healthcare testing within five years.